Cargando…

Immunosupportive therapies in aging

The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fülöp, Tamas, Larbi, Anis, Hirokawa, Katsuiku, Mocchegiani, Eugenio, Lesourd, Bruno, Castle, Stephen, Wikby, Anders, Franceschi, Claudio, Pawelec, Graham
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684090/
https://www.ncbi.nlm.nih.gov/pubmed/18044074
_version_ 1782167165146759168
author Fülöp, Tamas
Larbi, Anis
Hirokawa, Katsuiku
Mocchegiani, Eugenio
Lesourd, Bruno
Castle, Stephen
Wikby, Anders
Franceschi, Claudio
Pawelec, Graham
author_facet Fülöp, Tamas
Larbi, Anis
Hirokawa, Katsuiku
Mocchegiani, Eugenio
Lesourd, Bruno
Castle, Stephen
Wikby, Anders
Franceschi, Claudio
Pawelec, Graham
author_sort Fülöp, Tamas
collection PubMed
description The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment.
format Text
id pubmed-2684090
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26840902009-06-04 Immunosupportive therapies in aging Fülöp, Tamas Larbi, Anis Hirokawa, Katsuiku Mocchegiani, Eugenio Lesourd, Bruno Castle, Stephen Wikby, Anders Franceschi, Claudio Pawelec, Graham Clin Interv Aging Review The primary role of the immune system is to protect the organism against pathogens, but age-associated alterations to immunity increase the susceptibility of the elderly to infectious disease. The exact nature of these changes is still controversial, but the use of screening procedures, such as the SENIEUR protocol to exclude underlying illness, helped to better characterize the changes actually related to physiological aging rather than pathology. It is generally agreed that the most marked changes occur in the cellular immune response reflecting profound alterations in T cells. Much of this is due to thymic involution as well as changes in the proportions of T cell subpopulations resulting from antigen exposure, and altered T cell activation pathways. However, a body of data indicates that innate immune responses, including the critical bridge between innate and adaptive immunity, and antigen presenting capacity are not completely resistant to senescence processes. The consequences of all these alterations are an increased incidence of infections, as well as possibly cancers, autoimmune disorders, and chronic inflammatory diseases. The leading question is what, if anything, can we do to prevent these deleterious changes without dangerously dysregulating the precarious balance of productive immunity versus immunopathology? There are many potential new therapeutic means now available to modulate immunosenescence and many others are expected to be available shortly. One main problem in applying these experimental therapies is ethical: there is a common feeling that as ageing is not a disease; the elderly are not sick and therefore do not require adventurous therapies with unpredictable side-effects in mostly frail individuals. Animal models are not helpful in this context. In this chapter we will first briefly review what we think we know about human immunosenescence and its consequences for the health status of elderly individuals. We will then discuss possible interventions that might one day become applicable in an appropriate ethical environment. Dove Medical Press 2007-03 2007-03 /pmc/articles/PMC2684090/ /pubmed/18044074 Text en © 2007 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Fülöp, Tamas
Larbi, Anis
Hirokawa, Katsuiku
Mocchegiani, Eugenio
Lesourd, Bruno
Castle, Stephen
Wikby, Anders
Franceschi, Claudio
Pawelec, Graham
Immunosupportive therapies in aging
title Immunosupportive therapies in aging
title_full Immunosupportive therapies in aging
title_fullStr Immunosupportive therapies in aging
title_full_unstemmed Immunosupportive therapies in aging
title_short Immunosupportive therapies in aging
title_sort immunosupportive therapies in aging
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684090/
https://www.ncbi.nlm.nih.gov/pubmed/18044074
work_keys_str_mv AT fuloptamas immunosupportivetherapiesinaging
AT larbianis immunosupportivetherapiesinaging
AT hirokawakatsuiku immunosupportivetherapiesinaging
AT mocchegianieugenio immunosupportivetherapiesinaging
AT lesourdbruno immunosupportivetherapiesinaging
AT castlestephen immunosupportivetherapiesinaging
AT wikbyanders immunosupportivetherapiesinaging
AT franceschiclaudio immunosupportivetherapiesinaging
AT pawelecgraham immunosupportivetherapiesinaging